Albert Agustinus

Albert Augustinus questioned the sales force allocation strategy for Optune Pax, specifically whether new commercial team members are being recruited or if the launch will rely on reallocating the existing commercial team.

Answer

CEO Frank Leonard confirmed that Novocure is leveraging its established torso sales force, which was previously trained for Optune Lua, to lead the Optune Pax launch. He stated that no incremental sales headcount is being added at this time.

Albert Augustinus, on behalf of Jonathan Chang, inquired about the sales force allocation for Optune Pax, specifically asking if new commercial team members were recruited or if it involved a reallocation of the current commercial team.

Answer

CEO Frank Leonard stated that Novocure is leveraging its existing, established team, previously trained for Optune Lua, to lead the Optune Pax pancreatic launch, without adding incremental sales headcount at this time.

Albert Agustinus asked about Revolution Medicines' plans to advance the daraxonrasib combination in first-line non-small cell lung cancer (NSCLC), specifically inquiring if the company is still guiding towards the initiation of a registrational trial in this setting.

Answer

Chairman and CEO Mark A. Goldsmith affirmed the high commitment to developing daraxonrasib in first-line lung cancer. President of Research and Development Steve Kelsey elaborated that the company is exploring multiple options, including dose optimization with expected combination partners and efficacy testing to achieve the necessary proof of concept for a large Phase III trial. He committed to sharing more information later this year. Mark A. Goldsmith also noted the potential impact of the recently initiated ivonesimab combination studies on their lung cancer strategy.

Albert Agustinus asked for clarification on Revolution Medicines' plans to advance daraxonrasib combination therapy in first-line non-small cell lung cancer (NSCLC) and whether a registrational trial initiation is still expected this year.

Answer

Mark Goldsmith, Chairman and CEO, reiterated commitment to daraxonrasib in first-line lung cancer. Steve Kelsey, President of Research and Development, explained that Revolution Medicines is optimizing daraxonrasib's dose with combination partners and conducting efficacy testing to gather proof of concept for a large Phase 3 trial. He committed to sharing more information this year, noting that the ivonesimab combination also impacts their strategy.

Albert Agustinus, on behalf of Jonathan Chang at Leerink Partners, sought confirmation on whether the company is still on track to present data for the TEBI-AM study in the second half of 2026.

Answer

David Berman, EVP of R&D, confirmed they are on track to complete randomization for TEBI-AM, but the data readout is event-driven. He reiterated the speculation for a readout in the second half of 2026 but noted the timeline will become more precise as more events are accrued over the next six to nine months.

Albert Agustinus, on behalf of Jonathan Chang, asked for the company's reasons for confidence in its ability to reach its full-year revenue guidance.

Answer

Richard Paulson, President and CEO, stated that despite the $5 million atypical return impact, the company is confident in reaching the lower end of its guidance. This confidence is based on 5% year-over-year U.S. demand growth for XPOVIO and strong growth from its global partners.